Endocrine Abstracts

The TSH B/I ratio is normally reduced overnight and is substantially reduced in patients with overt central hypothyroidism due to h-p axis tumours before and after treatment. It is unknown if similar changes in the TSH B/I ratio in the absence of overt central hypothyroidism contribute to the increased TSH levels seen in cancer survivors who undergo h-p axis irradiation. Thus, we selected 9 patients with the highest TSH levels out of a previously reported cohort of 37 euthyroi...

Carpal tunnel syndrome (CTS) in acromegaly is caused, in part, by median nerve (MN) swelling. Pegvisomant (Peg), a growth hormone receptor (GHR) antagonist, lowers serum insulin-like growth factor-I (IGF-I) concentrations in patients with acromegaly, but serum GH levels rise and Peg is detected by most GH assays. Demonstrating that normalisation of serum IGF-I by Peg is associated with improvement/reversal of the consequences of GH excess is desirable. We documented changes in...

Introduction: There is no clear indication for radioiodine treatment (RAI) in patients affected by differentiated thyroid cancer (DTC) in Stage I and ATA intermediate risk, according to American Thyroid Association (ATA) guidelines.Purpose: Our aim is to evaluate whether integration of BRAF status and thyroglobulin TSH-stimulated at the time of RAI (A-HTg) could further improve accuracy of stratification, and therefore therapeutic management, in DTC pati...

Background: Obesity represents a cardiovascular risk factor. Monocyte chemoattractant protein-1 (MCP-1) is a known regulator of monocyte recruitment to sites of inflammation, and participates at the early phases of atherogenesis. Apolipoproteins, as part of the lipoprotein particles, are classically coupled with cardiovascular risk distinction.Aims: To assess the association of anthropometric parameters, insulin resistance and MCP-1 levels with classic l...

Context: Assessment of disease control in acromegaly depends on GH and IGF-I, but discordant values frequently occur. Further, the role of OGTT-suppressed GH (GHnadir) in somatostatin analogue (SA) treated patients is debated.Objective: To evaluate the effect of targeting either IGF-I or GH during SA treatment.Design: A randomized, investigator-initiated, multicentre trial.Patients and methods: 84 ...

In patients with adult growth hormone deficiency (AGHD), the dose of growth hormone (GH) replacement is individualised based on clinical outcome, insulin-like growth factor-I (IGF-I) levels and adverse reactions. The aim of this analysis was to characterise dose–IGFI–response for somapacitan, a long-acting reversible albumin-binding GH derivative, and to derive expected IGF-I levels for various starting doses. Somapacitan dose–IGF-I–response analysis wa...

Context: Serum IGF-binding protein-3 (IGFBP-3) and molar IGF-I to IGFBP-3 ratio can aid the diagnosis of GH-related diseases. However, their clinical utility is limited by lack of validated reference intervals.Objectives: To establish age-, gender- and Tanner stage-specific reference intervals for IGFBP-3 and IGF-I to IGFBP-3 ratio for Indian ethnicity.Setting and Participants: We conducted a cross-sectional epidemiological study (...

Women with polycystic ovary syndrome (PCOS) have higher prevalence of metabolic disturbances such as changes in lipid profile, diabetes, hypertension and metabolic syndrome. Variants on vitamin D receptor (VDR) gene have also been related to metabolic comorbidities in general population. Therefore, the aim of the present study was to investigate whether Apa-I polymorphism (rs7974232) in the VDR gene is associated with metabolic syndrome and endocrine profile in PCOS. In this c...

Vitamin D is a secosteroid hormone known for its skeletal effects. Recently, the extraskeletal effects of vitamin D are under investigation. Vitamin D is thought to exert an immunomodulatory effect, having multiple effects on the immune system. It is known to induce immune tolerance and also to enhance the immune response to bacteria.The aim was to study the effect of 1,25(OH)2D3 on interferon I secretion by human mononuclear cells ...

Background: The diagnosis of growth hormone deficiency (GHD) is based on a combination of clinical suspicion supported by growth hormone stimulation testing. IGF-1 and IGFBP-3 are used as supportive markers. Reports over the last decade have examined the performance of IGF-I and IGFBP-3 in the diagnosis of GHD. It is important that each unit evaluates the utility of these markers in the assay used by their laboratory based on relevant normative data.Aim:...